Partner Therapeutics

Lexington, United States Founded: 2017 • Age: 9 yrs
Partner Therapeutics is focused on developing and commercializing therapeutics for cancer and serious diseases.

About Partner Therapeutics

Partner Therapeutics is a Healthcare company based in Lexington (United States) founded in 2017. Partner Therapeutics is focused on developing and commercializing therapeutics for cancer and serious diseases. It operates on a HealthTech and Direct-to-Consumer (D2C) model. Partner Therapeutics has raised $60 million across 1 funding round from investors including MidCap Financial, Perceptive Advisors and Adams Street Partners. The company has 168 employees. Partner Therapeutics has completed 1 acquisition, including LEUKINE. Partner Therapeutics offers products and services including IMREPLYS® (sargramostim, rhu GM-CSF), Zenocutuzumab-zbco (BIZENGRI®), and LEUKINE. Its focus areas include Biotechnology and Cancer Therapeutics. Its legal entity is Partner Therapeutics, Inc. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.

Company details

Partner Therapeutics, an integrated biotechnology company, is engaged in the development and commercialization of late-stage therapeutics aimed at improving health outcomes for cancer and other serious diseases. The company is also involved in creating host-directed therapeutic treatments for global health security threats. Their work spans across supporting medical teams and delivering products with a focus on achieving superior patient outcomes. Research and clinical trials are conducted to evaluate and advance their therapeutic solutions like IMREPLYS for radiation exposure and Zenocutuzumab for NRG1 cancer.

  • Headquarters Lexington, United States
  • Employees 168
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website partnertx.com
  • Social LinkedIn X Facebook
  • Legal Name Partner Therapeutics, Inc.
Operational Areas
Key Metrics
  • Total Equity Funding
    $60M (USD)

    in 1 rounds

  • Latest Funding Round
    $60M (USD), Series A

    Feb 2018

  • Investors
  • Employee Count
    168
  • Investments & Acquisitions

Products & Services of Partner Therapeutics

Partner Therapeutics offers a comprehensive portfolio of products and services, including IMREPLYS® (sargramostim, rhu GM-CSF), Zenocutuzumab-zbco (BIZENGRI®), and LEUKINE.

IMREPLYS® (sargramostim, rhu GM-CSF)
Therapeutics

Used for treating radiation exposure in hematology cases.

Zenocutuzumab-zbco (BIZENGRI®)
Therapeutics

Developed for treating NRG1+ cancer in patients.

LEUKINE
Therapeutics

Licensed therapeutic for serious disease treatment support.

Funding Insights of Partner Therapeutics

Partner Therapeutics has successfully raised a total of $60M through 1 strategic funding round. The most recent funding activity was a Series A round of $60 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $60M
  • Total Rounds 1
  • Last Round Series A — $60M
  • First Round $60M

    (Feb 2018)

  • Investors Count 3

All 1 funding rounds of Partner Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2018$60MSeries A–Perceptive Advisors
Valuation history

3 investors in total: 3 institutional.

Investors in Partner Therapeutics

Partner Therapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include MidCap Financial, Perceptive Advisors and Adams Street Partners.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Health-tech companies are targeted for venture capital investments.
1999perceptivelife.comNew York, United States
Private markets investment management with strategies in equity, credit, and secondary investments.
adamsstreetpartners.com
Private debt funds are managed across multiple sectors.
2008midcapfinancial.comBethesda, United States
Premium access

Investor details for Partner Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Partner Therapeutics

59 people are tracked at Partner Therapeutics (30 in leadership, 29 in team); the tracked headcount is 168.

NameRoleGroup
Bronte Abraham
Senior Director, Operations (compliance, Commercial, Medical And Strategy)Leadership
Robert Mulroy
CEOLeadership
Sarah Kurz
President And Chief Operating OfficerLeadership
Bill McClements
Chief Financial & Operations OfficerLeadership
James Picardi
Director, Market Access (payer, Gpo, Specialty Pharmacy) - OncologyLeadership
Danielle Pettigrew, MS
Director, Market Access (gpo, Reimbursement, Value, Patient Services)Leadership
Jay Harding, PACS
Sr. Director, Market Access & National AccountsLeadership
Scott Armondino
Senior Director, Business Technology and OperationsLeadership
Sandy D.
Vice President, Commercial OperationsLeadership
Melanie Dyjak, M.S.
Associate Director, Clinical OperationsLeadership
Sanjeev Ahuja, MD, MBA, FACP
Chief Development Officer: Neurology, Critical Care and Health SecurityLeadership
Jeff Minor
Director, Corporate Accounts - OncologyLeadership
Matt Nestor
Vice President, New Product Planning and Product Team LeaderLeadership
Steven McAdams
Associate Director: Health, Safety, Security, EnvironmentLeadership
Jeff Gardin
Associate Director, TechnologyLeadership
John McManus
Chief Business OfficerLeadership
Debasish Roychowdhury
CTOLeadership
Emil Cakiryan
Associate Director, Financial Operations And Fp&aLeadership
Pat Thompson
National Accounts DirectorLeadership
John Mulroy
Senior Vice President Finance, TreasurerLeadership

39 more people are available in the full profile.

Premium access

Complete people profiles for Partner Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Partner Therapeutics

Partner Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include LEUKINE.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Information on infection drugs is provided via the Leukine website.
leukine.comBoston, United States1998Jan 2018••••
Premium access

Complete acquisition details for Partner Therapeutics

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Partner Therapeutics

3 dated milestones of Partner Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.

  1. Founded Partner Therapeutics is founded.
  2. Acquisition Acquires LEUKINE.
  3. Funding First funding round of $60.0M.

Competitors of Partner Therapeutics

Partner Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
revmed.com2014Redwood, United States$326.29M181
Cancer therapies are developed using selective pathway inhibitors.
blueprintmedicines.com2008Cambridge, United States$115M201
Selective kinase inhibitors are developed for genomically defined cancers.
syndax.com2005Waltham, United States$198.29M107
Targeted therapies for cancer treatment are developed.
Premium access

Detailed competitors of Partner Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Partner Therapeutics

The website of Partner Therapeutics (partnertx.com) receives about 5.6K visits a month.

  • Monthly visits
    5.6K

    ▲ 31.6% vs previous month

Top companies in Oncology

3 companies that operate in the same segment as Partner Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Partner Therapeutics

Premium access

Complete news archive for Partner Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Partner Therapeutics

Partner Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Partner Therapeutics is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.

Partner Therapeutics is a funded company, having raised a total of $60M across 1 funding round to date. The company's 1st funding round was a Series A of $60M, raised on Feb 2018.

Partner Therapeutics has 168 employees.

Partner Therapeutics, an integrated biotechnology company, is engaged in the development and commercialization of late-stage therapeutics aimed at improving health outcomes for cancer and other serious diseases. The company is also involved in creating host-directed therapeutic treatments for global health security threats. Their work spans across supporting medical teams and delivering products with a focus on achieving superior patient outcomes. Research and clinical trials are conducted to evaluate and advance their therapeutic solutions like IMREPLYS for radiation exposure and Zenocutuzumab for NRG1 cancer.

Partner Therapeutics's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.

Partner Therapeutics offers IMREPLYS® (sargramostim, rhu GM-CSF), Zenocutuzumab-zbco (BIZENGRI®), and LEUKINE.

Partner Therapeutics has made 1 acquisition, including LEUKINE.

Partner Therapeutics has 3 investors. Key investors include MidCap Financial, Perceptive Advisors, and Adams Street Partners.

Partner Therapeutics operates through Partner Therapeutics, Inc..

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available